Poly-MVA
| Against allopathy Alternative medicine |
|
| Clinically unproven |
| Woo-meisters |
Poly-MVA (or Polydox) is a dietary supplement created by Merrill Garnett (b. 1931), a former dentist turned biochemist. Poly-MVA is an ineffective alternative cancer treatment.[1]
Description[edit]
The "MVA" in "Poly-MVA" means "minerals vitamins and amino acids".[1] Poly-MVA contains lipoic acid, acetylcysteine, palladium, B vitamins, and other ingredients.[2] The substance is red-brown liquid that is taken by mouth.[1] Promoters of Poly-MVA refer to it as a "metallo-vitamin".[1]
In 2004, a year's supply of Poly-MVA was reported as costing US$19,800.[3]
Alternative medicine[edit]
Poly-MVA is promoted with claims that it can treat a variety of human diseases including cancer and HIV/AIDS.[1] The promotional effort is supported by customer testimonials, but there is no medical evidence that Poly-MVA confers any health benefit and some concern it may inhibit the effectiveness of mainstream cancer treatments if used at the same time.[1][2]
In 2005, Poly-MVA was listed as one of the ineffective alternative cancer treatments being sold by the clinics clustered in and around Tijuana, Mexico.[4]
External links[edit]
- Website of the distributors of POLY-MVA : AMARC Enterprises ... http://www.polymva.com
- Video from Cancer Free University of CEO of AMARC Enterprises, Al Sanchez Jr, talking about POLY-MVA ... https://vimeo.com/215357706
- Apparently Al Sanchez Jr has promoted POLY-MVA since 2001
See also[edit]
References[edit]
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Russell J, Rovere A, ed (2009). "Poly-MVA". American Cancer Society Complete Guide to Complementary and Alternative Cancer Therapies (2nd ed.). American Cancer Society. pp. 804-807. ISBN 9780944235713.
- ↑ 2.0 2.1 "Polydox". Herb-drug Interactions in Oncology. PMPH-USA. 2010. p. 536. ISBN 978-1-60795-041-7.
- ↑ "Is this cancer-fighting supplement too good to be true?". Women's Health Letter (May): 4. 2004.
- ↑ Moss, R. W. (2005). "Patient Perspectives: Tijuana Cancer Clinics in the Post-NAFTA Era". Integrative Cancer Therapies 4 (1): 65–86. PMID 15695477.